Tryptophan research in panic disorder.

A considerable body of evidence suggests the involvement of serotonin neurotransmission in the pathogenesis of panic disorder. Research on pathways and functions of tryptophan, an essential amino acid converted into serotonin, may advance our understanding of serotonergic actions in panic disorder and related phenomena. The investigative approaches in this field include manipulations of tryptophan availability as well as genetic association and functional brain imaging studies. In this review we examine the principle findings of these studies and propose further research directions

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is an important cardiovascular disease with sudden cardiac death as the most devastating presentation. Implantable cardioverter defibrillators (ICD) are the optimal therapy for prevention of sudden death from ventricular tachycardia or fibrillation of any cause. While there is no controversy with implanting ICDs in patients who have already survived a cardiac arrest, identifying high-risk patients for primary prevention in this disease remains a challenge. Implanting ICDs in patients with HCM is an important clinical consideration since many individuals could achieve normal or near-normal lifespans with this protection

Carbon Free Boston: Offsets Technical Report

Part of a series of reports that includes: Carbon Free Boston: Summary Report; Carbon Free Boston: Social Equity Report; Carbon Free Boston: Technical Summary; Carbon Free Boston: Buildings Technical Report; Carbon Free Boston: Transportation Technical Report; Carbon Free Boston: Waste Technical Report; Carbon Free Boston: Energy Technical Report; Available at http://sites.bu.edu/cfb/OVERVIEW: The U.S. Environmental Protection Agency defines offsets as a specific activity or set of activities intended to reduce GHG emissions, increase the storage of carbon, or enhance GHG removals from the atmosphere [1]. From a city perspective, they provide a mechanism to negate residual GHG emissions— those the city is unable to reduce directly—by supporting projects that avoid or sequester them outside of the city’s reporting boundary. Offsetting GHG emissions is a controversial topic for cities, as the co-benefits of the investment are typically not realized locally. For this reason, offsetting emissions is considered a last resort, a strategy option available when the city has exhausted all others. However, offsets are likely to be a necessity to achieve carbon neutrality by 2050 and promote emissions reductions in the near term. While public and private sector partners pursue the more complex systems transformation, cities can utilize offsets to support short-term and relatively cost-effective reductions in emissions. Offsets can be a relatively simple, certain, and high-impact way to support the transition to a low-carbon world. This report focuses on carbon offset certificates, more often referred to as offsets. Each offset represents a metric ton of verified carbon dioxide (CO2) or equivalent emissions that is reduced, avoided, or permanently removed from the atmosphere (“sequestered”) through an action taken by the creator of the offset. The certificates can be traded and retiring (that is, not re-selling) offsets can be a useful component of an overall voluntary emissions reduction strategy, alongside activities to lower an organization’s direct and indirect emissions. In the Global Protocol for Community-Scale Greenhouse Gas Emissions Inventories (GPC), the GHG accounting system used by the City of Boston, any carbon offset certificates that the City has can be deducted from the City’s total GHG emissions.http://sites.bu.edu/cfb/files/2019/06/CFB_Offsets_Technical_Report_051619.pdfPublished versio

Cardiovascular Diseases That Have Emerged From the Darkness

It is important for both the patient and physician communities to have timely access to information recognizing rapid progress in the diagnosis and treatment of familiar but relatively uncommon cardiovascular diseases. Patients with 3 cardiovascular diseases (ie, hypertrophic cardiomyopathy, pulmonary arterial hypertension, and transthyretin (TTR) cardiac amyloidosis (ATTR)]), once considered rare without effective management options and associated with malignant prognosis, have now benefited substantially from the development of a variety of innovative therapeutic strategies. In addition, in each case, enhanced diagnostic testing has expanded the patient population and allowed for more widespread administration of contemporary treatments. In hypertrophic cardiomyopathy, introduction of implantable defibrillators to prevent sudden death as well as high-benefit:low-risk septal reduction therapies to reverse heart failure have substantially reduced morbidity and disease-related mortality (to 0.5% per year). For pulmonary arterial hypertension, a disease once characterized by a particularly grim prognosis, prospective randomized drug trials with aggressive single (or combined) pharmacotherapy have measurably improved survival and quality of life for many patients. In cardiac amyloidosis, development of disease-specific drugs can for the first time reduce morbidity and mortality, prominently with breakthrough ATTR-protein-stabilizing tafamidis. In conclusion, in less common and visible cardiovascular diseases, it is crucial to recognize substantial progress and achievement, given that penetration of such information into clinical practice and the patient community can be inconsistent. Diseases such as hypertrophic cardiomyopathy, pulmonary arterial hypertension, and ATTR cardiac amyloidosis, once linked to a uniformly adverse prognosis, are now associated with the opportunity for patients to experience satisfactory quality of life and extended longevity

Arresting woodland bird decline in Australian agricultural landscapes: potential application of the European agri-environment model

This paper considered the applicability of the European model of land stewardship payments, in particular its support for biodiversity conservation in agricultural landscapes, to an Australian context. More broadly, the research approach described in the paper may also be applied to assessing the suitability of overseas stewardship schemes to the provision of any ecoservice in Australia, such as carbon sequestration and floodwater regulation

From Small-Scale Dynamo to Isotropic MHD Turbulence

We consider the problem of incompressible, forced, nonhelical, homogeneous, isotropic MHD turbulence with no mean magnetic field. This problem is essentially different from the case with externally imposed uniform mean field. There is no scale-by-scale equipartition between magnetic and kinetic energies as would be the case for the Alfven-wave turbulence. The isotropic MHD turbulence is the end state of the turbulent dynamo which generates folded fields with small-scale direction reversals. We propose that the statistics seen in numerical simulations of isotropic MHD turbulence could be explained as a superposition of these folded fields and Alfven-like waves that propagate along the folds.Comment: kluwer latex, 7 pages, 7 figures; Proceedings of the International Workshop "Magnetic Fields and Star Formation: Theory vs. Observations", Madrid, 21-25 April 2003 -- published version (but the e-print is free of numerous typos introduced by the publisher